and cytotoxicity, and in inhibiting tumor growth in vivo. This process of designing and developing synthetic adjuvants has been named "adjuvant engineering", and the evaluation and improvement of P2C-RGDS is the first step in developing a stronger synthetic adjuvant in the future.
Introduction
Recently, bacterial adjuvants used for cancer immunotherapy in the 1970s as biological response modifiers (BRM) have been re-evaluated. [1] [2] [3] Cancer antigens that had been identified in many laboratories were tested as peptide vaccines for clinical applications, but the peptides alone did not activate the immune system enough. 4 These results suggested that the activation of the innate immune system, including dendritic cells (DCs), by a supporting adjuvant was important. [5] [6] [7] [8] In peptide vaccine therapy, T cells of the acquired immune system play an important role in attacking the tumor. 9 DCs have a key role in an initial start of immune systems to an antigen and control the acquired immune system. The identification of the Toll-like receptor (TLR) family advanced the understanding of DC function and of adjuvants, because almost all microbial adjuvants work as TLR ligands and activate DCs. [10] [11] [12] These findings provide a mechanism for adjuvant therapy.
Dr. Azuma developed BCG-CWS, a cell-wall skeleton preparation of
Mycobacterium bovis bacillus Calmette-Guérin, 13, 14 as an anticancer immunotherapeutic adjuvant. Although many studies of BRM have been discontinued, basic and clinical research on BCG-CWS have continued at Osaka Medical Center for Cancer. We reported that BCG-CWS is a ligand of TLR2/4 (refs. 15, 16, 17) and acts as an effective adjuvant to induce CTLs when treated with irradiated tumors in a mouse experimental model. These 6 activities are mediated via myeloid differentiation protein 88 (MyD88), 18 which is a TLR adaptor molecule. The effectiveness of BCG-CWS in improving the prognosis for cancer patients after surgery was confirmed in our clinical research. 19 Interleukin (IL)-23 and interferon (IFN)- are the main cytokines induced by BCG-CWS in vivo 14, 19, 20 and are important for antitumor immunity. 21, 22 IL-12 is well known as an anticancer cytokine, 23 and IL-23
shares the IL12p40 subunit with IL-12. [24] [25] [26] . However, it was also reported that systemic administration of IL-23 produces antitumor effects similar to those of IL-12, 27 and TLR2 ligands exhibit antitumor activity [28] [29] [30] that may be mediated by the induction of IL-23.
Although BCG-CWS is an effective adjuvant, it cannot be chemically synthesized and is prepared from bacterial cells, there is a problem in purity, stability and stable supply. Therefore, there is a need to develop new synthetic adjuvants as effective as BCG-CWS that can be stably produced. We have designed such adjuvants based on the structure of the TLR2 ligand and in consideration of the need for IL-23 induction. MALP-2, a lipopeptide of mycoplasmic origin, is a TLR2 ligand that can be chemically synthesized. No functional consensus sequences were identified in MALP-2. The N-terminal 7 cysteine of the 13-amino-acid peptide of bacterial origin was modified with 2 palmitates (Pam2Cys or P2C), 31 but P2C alone does not work as a TLR2 ligand. 32 Bacterial and synthetic TLR2 ligands (MALP-2, FSL   32   ,   P2C-SKKKK   33 ) contain mostly hydrophilic peptides, and the presence of solubilizers critically affects their TLR2 agonistic ability, 34 suggesting that the activity of compounds as TLR2 agonists correlates with their solubility.
CD11c is a member of the integrin superfamily and is known to be a marker of DCs. 35 DCs also express other integrin molecules such as V/3
and 5/1, and the RGDS motif specifically binds to these integrins. 36 Virus particles expressing proteins containing the RGD motif efficiently infect DCs. 37 Therefore, we developed a new TLR2 ligand by replacing the peptide of bacterial origin with a hydrophilic functional motif (adjuvant engineering).
We linked P2C and the RGDS peptide to increase the efficiency of ligand adherence to DCs or other immune cells, and examined the effect of the new adjuvant on antitumor activities in vitro and in vivo. 8 
Materials and Methods
Mice, cells, and reagents TICAM-1 -/-mice were generated in our laboratory. 
MyD88
-/-mice were provided by Shizuo Akira (Osaka Univ.). 38 The mice were maintained under specific pathogen-free conditions in the animal facility of the Osaka Medical Center. They were backcrossed with C57BL/6 mice >8 times before use. Wild-type C57BL/6 mice were purchased from Japan Clea (Tokyo, Japan). All animal experiments were consented by the committee in our institute. EG7 cells are ovalbumin-transfected EL4 and were obtained from ATCC (Manassas, VA, USA). 39 Cell lysates were prepared by the freeze-thawing method.
Preparation of mouse BMDCs, splenocytes, and lymph node cells Bone marrow-derived DCs (BMDCs) were prepared as reported 35, 40 with minor modifications. BMDCs were cultured in RPMI-1640 (Invitrogen, Carlsbad, CA) containing 10 ng/ml mouse granulocyte-macrophage colony-stimulating factor (PeproTech EC Ltd., London, UK), and 50 μM 2-mercaptoethanol (Invitrogen, Carlsbad, CA), 10 mM HEPES and 10% FCS (Bio Whittaker, Walkersville, MD). The lymph node cells and splenocytes were prepared from inguinal lymph nodes and spleens of mice by using Cr release assay. 18 The percentage of specific lysis was calculated using the formula: %Specific lysis = [(experimental release -spontaneous release)/(total release -spontaneous release)]  100. The ratios of CD8-positive in lymph node cells, and of CD4 or CD8-positive in splenocytes were analyzed by FACS.
Results
To design a new TLR2 ligand with activity equivalent to BCG-CWS, we connected the minimum lipopeptide unit, P2C, to the RGDS integrin-binding motif to increase adherence to DCs (Fig. 1a) . The hydrophobicity and pI of P2C-RGDS were similar to those of MALP-2, and the molecular weight of P2C-RGDS was half that of MALP-2 (Fig. 1b) .
First, we evaluated whether these synthetic adjuvants activated BMDCs in vitro when these compounds were simply added to the culture medium. The P2C-RGDS enhanced the expression of CD80 and CD86 on BMDCs to a level equal to that of MALP-2, the positive control (Fig. 2a) , whereas P2C did not. P2C-RGDS also enhanced the production of IL12p40 and TNF-α ( (Fig. 3) , suggesting that P2C-RGDS is a TLR2 ligand with activity similar to that of MALP-2 in vitro.
To test whether the function of P2C-RGDS as a TLR2 ligand depends 13 not only on its hydrophilicity, but also on the motif-specificity of the peptide sequences, we performed peptide-dependent inhibition assays. At first, the inhibition peptide did not work in any experiments when DCs were treated with each compound for 24 h (data not shown); therefore, we changed the DC stimulation conditions to affect the adherence of the compounds. DCs were treated with each compound at 4°C for 1 h, then washed and recultured for 24
h. The addition of RGDS peptide partially attenuated the expression of CD86 on BMDCs induced by P2C-RGDS, but not that induced by MALP-2 ( Fig.   4a ). This result indicates that the hydrophilicity of RGDS is a major contributor to the in vitro stimulation of DCs, but the function of the RGDS motif also weakly contributes to its activity.
Next, we evaluated the activities of P2C-RGDS using in vitro whole splenocyte stimulation and an in vivo tumor-implantation model. Although the activities of P2C-RGDS and MALP-2, as measured by IFN- production, were almost the same and were weaker than BCG-CWS when splenocytes were simply stimulated with each compound for 72 h (Fig. 4b) . Then we evaluated the inhibitory effect of IFNγ production of splenocytes under 4°C for 1 h. P2C-RGDS induced IFNγ more strongly than MALP-2 and its Fig. 5d) . Although the necrosis appeared on surface of tumor by P2C-RGDS but not MALP-2 treatment, and CD8-positive cells were detected around necrosis area by immunostaining (data not shown). These 15 data suggest that P2C-RGDS induces and activates CTL more efficiently than MALP-2.
Discussion
It has been reported that natural TLR2 ligands of bacterial origin, such as FSL-1 and MALP-2, effectively activate CD8-positive T cells and induce antitumor activity. Because these lipopeptides are hydrophilic, it was predicted that the hydrophilicity of the peptide might be important for its activity. [31] [32] [33] [34] Many researchers have used a chemobiologic strategy of making amino acid replacements in nature bacterial lipopeptide to explore which lipopeptide peptide sequences provide effective adjuvant activity. 41 Using this strategy, Takeda Co Ltd. developed Tan-1511 analogues, which has high activity for the induction of granulopoiesis. 41 Another strategy has to randomly search for effective sequences or peptides that enhance TLR2 ligand activity. 42 The purpose of our current project was to develop as a new synthetic adjuvant a TLR2 ligand with an additional function through the addition of a hydrophilic, functional peptide (Fig. 1) . Our adjuvant-engineering project is a new strategy to incorporate biological findings into drug design.
We developed the compound P2C-RGDS, which was as effective as MALP-2 in generating BMDCs responses in vitro, such as the enhancement of a maturation marker (CD80 and CD86) and cytokine induction when DCs were cultured with each compound for 24-48 h (Fig. 2) . P2C-RGDS and MALP-2 activated DCs through MyD88 (Fig. 3) , which is a major TLR2 17 signal adaptor molecule. 38 In this study, although P2C-RGDS has an additional sequence (RGDS) that was required, in part, to activate DCs, P2C-RGDS and MALP-2 showed similar activities in vitro (Fig. 4) . We therefore predicted that the peptide sequence of MALP-2 may also adhere to DCs, because MALP-2 also activated BMDCs when incubated even at 4°C for 60 min. We also hypothesized that if the adhesive abilities of RGDS were not reflected in this simple experimental system, even though diffused lipopeptide stimulated DCs in culture medium, the differences might appear in vivo or in the responses of whole splenocytes stimulated with compounds for a short time. In fact, whole splenocytes stimulated with P2C-RGDS produced more IFN- than MALP-2 (Fig. 4) , and P2C-RGDS more effectively retarded tumor growth and induced CD8-positive cells than MALP-2 (Fig. 5) . The stronger IFN- induction by P2C-RGDS might be due to its retention in the culture system by adherence to various cells among the splenocytes. These data suggest that the adhesion efficiency of compounds also contributes to adjuvanticity and antitumor activity in vivo. In another experiments, the tumor volume of BCG-CWS treatment group was about 60% of control on day 22 (data not shown), the therapeutic effects of P2C-RGDS were almost equivalent to BCG-CWS. However BCG-CWS must be emulsified with drakeol, there is an advantage for P2CR to use easily.
The induction of IFN- production by BCG-CWS treatment is one of the indexes for continuing treatment in our clinical application 14, 19 , and the response can be confirmed in the mouse. IFN- stimulation upregulates the expression of MHC class I on tumor cells, 43 and therefore presumably Integrins are expressed on various tumor cells. 44 We confirmed that EG7 cells also express integrin V, 1, and 3 (data not shown). However, there was no direct cytotoxicity to EG7 cells treated with P2C-RGDS at concentrations up to 100 nM (data not shown). On this basis, we predict that these compounds exhibit their anticancer activity via activation of the immune system. Here, we examined whether including an integrin-binding motif in a 
